Phibro: 3 Key Takeaways for Long-Term Investors
Key Points
Mineral Nutrition sales grew 17% on higher commodity prices.
Animal Health segment sales increased 3% to $293 million.
Management kept net sales guidance at $1.5 billion to $1.6 billion.
- Motley Fool Issues Rare "Total Conviction" Buy Alert ›
On its first-quarter fiscal year 2027 earnings call, held on Nov. 5, 2026, Phibro (NASDAQ:PAHC) reported net sales of $386.8 million, up 6% year over year despite softness in the poultry market. Long-term investors need to track how the company shifts revenue into higher-margin specialty products while working down excess inventory. Three things management said stand out.
1. Non-Animal Health Segments Expand Into Higher-Margin Markets
Performance Products sales grew 16%, and Mineral Nutrition rose 17% during the quarter. Management is intentionally pivoting these business units toward plant nutrition, dairy, and pet food to build durable, higher-margin customer relationships.
Customers in these markets are asking for more on ingredient sourcing, quality, consistency and technical support.
-- Dani Bendheim, President and Chief Executive Officer
2. Poultry Margin Pressure Trims Short-Term Additive Demand
U.S. chicken supply grew over 2%, outpacing consumer demand and squeezing producer margins. Farm operators responded by trimming product inventories and pausing purchases of nutritional specialties and vaccines.
When margins tighten, customers look harder at every input cost they purchase.
-- Dani Bendheim, President and Chief Executive Officer
3. Management Focuses Capital Allocation on Inventory and Cash Flow
Free cash flow reached $22 million over the trailing 12 months, but excess inventory continues to tie up capital. Lowering inventory levels will unlock working capital to pay down debt and fund internal investments.
We were cash positive in the quarter, but I am not satisfied. We're carrying more inventory than we needed and bringing it down this year is a priority for me and for our whole team.
-- Dani Bendheim, President and Chief Executive Officer
Looking Ahead
Revenue momentum across specialty segments holds steady, supporting full-year financial guidance. Structural cost savings from facility consolidations and expanded distribution channels strengthen long-term unit economics.
In closing, we are pleased with the performance in our first quarter and the momentum we are carrying into the rest of fiscal year 2027.
-- Glenn David, Chief Financial Officer
Management expects protein producer margins to recover as crop harvest yields lower livestock feed expenses.
The underlying demand for chicken is there, and we do well when it is. We see this pullback as temporary, and we expect it to normalize over the course of this fiscal year.
-- Dani Bendheim, President and Chief Executive Officer
Should you buy stock in Phibro Animal Health right now?
Before you buy stock in Phibro Animal Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Phibro Animal Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $341,966!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,146,819!*
Now, it’s worth noting Stock Advisor’s total average return is 852% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 9, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
